Login to Your Account



Other News To Note


Monday, October 24, 2011
• Intarcia Therapeutics Inc., of Hayward, Calif., signed a letter of intent with contract research organization Quintiles Transnational Corp., of Research Triangle Park, N.C., to collaborate on the Phase III program for Intarcia's ITCA 650 (DUROS subcutaneous continuous delivery of exenatide). The program aims to demonstrate multiple advancements in GLP-1 therapy for Type II diabetes. Financial terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription